Cabaletta Bio shares CAR-T results in three autoimmune conditionsnews2025-06-11T15:29:34+00:00June 11th, 2025|Endpoints News|
Vaxart shares rise after reporting norovirus vaccine datanews2025-06-11T14:12:17+00:00June 11th, 2025|Endpoints News|
BMS’ RayzeBio bags rights for Philochem’s radiopharma asset for $350M upfrontnews2025-06-11T10:39:03+00:00June 11th, 2025|Endpoints News|
Argenx says its drug Vyvgart looks promising in two more autoimmune diseasesnews2025-06-11T00:57:18+00:00June 11th, 2025|Endpoints News|
FDA chief Makary says he wasn’t involved in decision to fire ACIP membersnews2025-06-10T18:46:31+00:00June 10th, 2025|Endpoints News|
FDA places hold on Gilead’s studies of HIV treatment pill combonews2025-06-10T15:09:36+00:00June 10th, 2025|Endpoints News|
Rebooting dead human brains, biotech seeks to reinvent drug testing worknews2025-06-10T14:00:49+00:00June 10th, 2025|Endpoints News|
FDA approves Merck’s RSV antibody drug for babiesnews2025-06-09T18:11:38+00:00June 9th, 2025|Endpoints News|
Federally-funded cancer research comes to a perilous crossroadsnews2025-06-09T17:21:34+00:00June 9th, 2025|Endpoints News|
Merck unveils Phase 3 data for oral PCSK9 inhibitor enlicitide decanoatenews2025-06-09T15:25:21+00:00June 9th, 2025|Endpoints News|
